Moderna (NASDAQ:MRNA) Price Target Lowered to $139.00 at The Goldman Sachs Group

Moderna (NASDAQ:MRNA) had its target price cut by The Goldman Sachs Group from $178.00 to $139.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also commented on MRNA. Deutsche Bank Aktiengesellschaft raised Moderna from a sell rating to a hold rating and cut their price target for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Bank of America cut their target price on shares of Moderna from $130.00 to $110.00 and set a neutral rating on the stock in a research report on Friday, September 13th. Evercore ISI restated an in-line rating and issued a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. JPMorgan Chase & Co. lowered shares of Moderna from a neutral rating to an underweight rating and cut their price target for the stock from $88.00 to $70.00 in a report on Friday, September 13th. Finally, William Blair restated a market perform rating on shares of Moderna in a report on Thursday, June 27th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Hold and a consensus target price of $100.44.

Moderna Trading Down 2.6 %

MRNA opened at $68.02 on Monday. The company has a market cap of $26.07 billion, a P/E ratio of -4.34 and a beta of 1.68. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The company’s 50 day moving average is $91.19 and its 200-day moving average is $110.97. Moderna has a 1-year low of $62.55 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the previous year, the firm posted ($3.62) earnings per share. The company’s revenue was down 29.9% on a year-over-year basis. Equities research analysts predict that Moderna will post -9.52 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the sale, the director now owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total value of $1,908,300.00. Following the completion of the sale, the director now directly owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 689 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the transaction, the chief financial officer now owns 7,269 shares in the company, valued at approximately $859,486.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 93,158 shares of company stock valued at $11,167,312. 15.70% of the stock is currently owned by company insiders.

Institutional Trading of Moderna

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Moderna by 22.6% during the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock worth $3,372,058,000 after buying an additional 6,248,623 shares during the last quarter. Norges Bank acquired a new stake in shares of Moderna in the 4th quarter worth about $347,565,000. Wellington Management Group LLP raised its holdings in shares of Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after acquiring an additional 1,614,460 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Moderna by 42.9% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after acquiring an additional 463,960 shares in the last quarter. Finally, Matrix Capital Management Company LP acquired a new position in Moderna during the 4th quarter valued at about $45,150,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.